文献速递基础与转化研究临床试验与 GCP

肾移植调节性细胞治疗(ONE Study):七项非随机单臂1/2A期试验的统一设计与分析

Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials.
PubMed 文献 · Lancet · 2020-01-01

ONE Study包含七项研究者主导的国际单臂试验,比较标准治疗组与六种调节性细胞产品组在活体肾移植受者中的安全性和排斥反应。主要终点为60周内活检证实的急性排斥(BCAR),标准治疗组BCAR率为12%,细胞治疗组总体为16%,细胞治疗组感染事件更少,40%患者成功停用霉酚酸酯。

要点

  • 调节性细胞治疗在活体肾移植受者中可行且安全,感染并发症更少。
  • 细胞治疗组60周内BCAR率为16%,标准治疗组为12%,排斥率相似。
  • 40%接受细胞产品的患者成功停用霉酚酸酯并维持他克莫司单药治疗。

核心结论

  • 调节性细胞治疗在活体肾移植受者中可实现且安全,感染并发症更少,但第一年排斥率相似。

研究设计与样本

  • 七项研究者主导的国际单臂试验,在法国、德国、意大利、英国和美国的八家医院进行,随访60周。
  • 纳入18岁及以上活体肾移植受者,参考组给予巴利昔单抗、渐减激素、霉酚酸酯和他克莫司。
  • 六项非随机1/2A期细胞治疗组试验汇总分析,患者接受含调节性T细胞、树突状细胞或巨噬细胞的六种细胞产品之一。
  • 细胞治疗组免疫抑制与参考组相似,但以细胞产品替代巴利昔单抗诱导,并允许霉酚酸酯减量。
  • 试验非随机且未设盲,主要终点为移植后60周内活检证实的急性排斥(BCAR)。

主要发现

  • 782例患者评估资格,130例(17%)入组,104例接受治疗并纳入分析。
  • 参考组66例接受治疗,73%为男性,中位年龄47岁;细胞治疗组38例接受治疗,71%为男性,中位年龄45岁。
  • 15例(40%)接受细胞产品的患者成功停用霉酚酸酯并维持他克莫司单药治疗。
  • 汇总不良事件和BCAR数据未发现与参考组相比的安全性问题,细胞治疗组感染事件更少。

关键数值与推荐

  • 主要终点为移植后60周内活检证实的急性排斥(BCAR)。
  • 15例(40%)接受细胞产品的患者成功停用霉酚酸酯并维持他克莫司单药治疗。

临床怎么用

  • 调节性细胞治疗可作为活体肾移植受者减少全身免疫抑制负担的潜在治疗选择。
  • 细胞治疗与标准治疗相比排斥率相似且感染并发症更少,但需进一步随机对照试验验证。

局限性

  • 试验为非随机设计,且未设盲。
  • 样本量较小,细胞治疗组仅38例接受治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Use of cell-based medicinal products (CBMPs) represents a state-of-the-art approach for reducing general immunosuppression in organ transplantation. We tested multiple regulatory CBMPs in kidney transplant trials to establish the safety of regulatory CBMPs when combined with reduced immunosuppressive treatment. METHODS: The ONE Study consisted of seven investigator-led, single-arm trials done internationally at eight hospitals in France, Germany, Italy, the UK, and the USA (60 week follow-up). Included patients were living-donor kidney transplant recipients aged 18 years and older. The reference group trial (RGT) was a standard-of-care group given basiliximab, tapered steroids, mycophenolate mofetil, and tacrolimus. Six non-randomised phase 1/2A cell therapy group (CTG) trials were pooled and analysed, in which patients received one of six CBMPs containing regulatory T cells, dendritic cells, or macrophages; patient selection and immunosuppression mirrored the RGT, except basiliximab induction was substituted with CBMPs and mycophenolate mofetil tapering was allowed. None of the trials were randomised and none of the individuals involved were masked. The primary endpoint was biopsy-confirmed acute rejection (BCAR) within 60 weeks after transplantation; adverse event coding was centralised. The RTG and CTG trials are registered with ClinicalTrials.gov, NCT01656135, NCT02252055, NCT02085629, NCT02244801, NCT02371434, NCT02129881, and NCT02091232. FINDINGS: The seven trials took place between Dec 11, 2012, and Nov 14, 2018. Of 782 patients assessed for eligibility, 130 (17%) patients were enrolled and 104 were treated and included in the analysis. The 66 patients who were treated in the RGT were 73% male and had a median age of 47 years. The 38 patients who were treated across six CTG trials were 71% male and had a median age of 45 years. Standard-of-care immunosuppression in the recipients in the RGT resulted in a 12% BCAR rate (expected range 3·2-18·0). The overall BCAR rate for the six parallel CTG trials was 16%. 15 (40%) patients given CBMPs were successfully weaned from mycophenolate mofetil and maintained on tacrolimus monotherapy. Combined adverse event data and BCAR episodes from all six CTG trials revealed no safety concerns when compared with the RGT. Fewer episodes of infections were registered in CTG trials versus the RGT. INTERPRETATION: Regulatory cell therapy is achievable and safe in living-donor kidney transplant recipients, and is associated with fewer infectious complications, but similar rejection rates in the first year. Therefore, immune cell therapy is a potentially useful therapeutic approach in recipients of kidney transplant to minimise the burden of general immunosuppression. FUNDING: The 7th EU Framework Programme.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Sawitzki B, Harden PN, Reinke P, et al. Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. Lancet. 2020. PMID: 32446407. doi:10.1016/S0140-6736(20)30167-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。